Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma

Genes

卷:13

Giovanna Cilluffo¹  Amelia Licari²  Giorgio Piacentini³  Giuliana Ferrante³  Salvatore Fasola⁴  Velia Malizia⁴  Stefania La Grutta⁴ 

[1] Department of Earth and Marine Sciences, University of Palermo, 90123 Palermo, Italy;

[2] Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy;

[3] Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Division, University of Verona, 37134 Verona, Italy;

[4] Institute of Translational Pharmacology, National Research Council, 90146 Palermo, Italy;

关键词: asthma;    β2-agonists;    children;    corticosteroids;    genetics;    leukotriene antagonists;   

DOI  :  10.3390/genes13040599

来源: DOAJ

【 摘 要 】

Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, along with patient pheno-endotypization, will increase our knowledge of several molecular mechanisms involved in asthma pathophysiology and contribute to selecting and stratifying appropriate treatment for each patient.

【 授权许可】

Unknown